Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo

Abstract

Adrenomedullin (ADM) is protumorigenic by stimulating tumor cell growth and angiogenesis. In this context, ADM is identified as a novel target for antiangiogenic therapy. In this study, we addressed the possibility that vinblastine (VBL), as demonstrated in other experimental conditions, may act as an angiostatic molecule in the angiogenic response induced by ADM in two assays, such as Matrigel tube formation in vitro and angiogenesis in the chick embryo chorioallantoic membrane (CAM) in vivo. When tested on Matrigel, ADM caused a morphogenetic effect. In fact, endothelial cells spread and aligned with each other to form branching anastomosing tubes with multicentric junctions that gave rise to a meshwork of capillary-like structures. When ADM was administered in the presence of VBL, the capillary-like tubes were interrupted, most cells were spherical, either isolated or aggregated in small clumps. In the CAM assay, ADM induced a strong angiogenic response, which was counteracted by the treatment with VBL. Overall, these observations implicate ADM as a promoter of tumor growth and a possible target for anticancer strategies, such as the use of VBL at very low, nontoxic doses. Nevertheless, the antiangiogenic acitivity of low-dose VBL deserves further investigation, alone or together with other antiangiogenic agents for the treatment of tumors characterized by enhanced angiogenesis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Belloni AS, Albertin G, Forneris ML and Nussdorfer GG . (2001). Histol. Histopathol., 16, 1263–1274.

  • Caron KM and Smithies O . (2001). Proc. Natl. Acad. Sci. USA, 98, 615–619.

  • El Hafny B, Cano N, Piciotti M, Regina A, Schermann JM and Roux F . (1997). Biochem. Pharmacol., 53, 1735–1745.

  • Fujita Y, Minata H, Nasu N, Nomura T, Nomura Y and Nakagawa M . (2002). Int. J. Urol., 9, 285–295.

  • Hague S, Zhang L, Oehler MK, Manek S, Mac Kenzie IZ, Bicknell R and Rees MC . (2000). Clin. Cancer Res., 6, 2808–2814.

  • Ishikawa T, Chen J, Wang J, Okada F, Sugiyama T, Kobayashi T, Shind M, Higashino F, Katoh H, Asaka M, Kondo T, Hosokawa M and Kobayashi M . (2003). Oncogene, 22, 1238–1242.

  • Kerbel R and Folkman J . (2002). Nat. Rev. Cancer, 2, 727–739.

  • Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P and Kerbel RS . (2000). J. Clin. Invest., 105, R15–R24.

  • Martinez A, Vos M, Gaudez L, Kaur G, Chen Z, Garayoa M, Pio R, Moody T, Stetler-Stevenson WG, Kleinman HK and Cuttitta F . (2002). J. Natl. Cancer Inst., 94, 1226–1237.

  • Minamino N, Kanagawa K and Matsuo H . (2000). Clin. Hemor. Microcirc., 23, 95–102.

  • Nikitenko LL, Smith DM, Hague S, Wilson CR, Bicknell R and Rees MCP . (2002). Trends. Pharm. Sci., 23, 101–103.

  • Oehler MK, Hague S, Rees MCP and Bicknell R . (2002). Oncogene, 21, 2815–2821.

  • Presta M, Rusnati M, Belleri M, Morbidelli L, Ziche M and Ribatti D . (1999). Cancer Res, 59, 2417–2424.

  • Presta M, Belleri M, Vacca A and Ribatti D . (2002). Leukemia, 16, 1490–1499.

  • Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L and Presta M . (1997). J. Vasc. Res., 34, 455–463.

  • Ribatti D, Vacca A and Dammacco F . (1999). Neoplasia, 1, 293–302.

  • Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, Imai Y, Ebihara A, Kuwaki T, Ju KH, Minamino N, Kangawa K, Ishikawa T, Fukuda M, Akimoto Y, Kawakami H, Imai T, Morita H, Yazaki Y, Nagai R, Hirata Y and Kurihara H . (2001). Circulation, 104, 1964–1971.

  • Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A and Dammacco F . (1999). Blood, 94, 4143–4155.

  • Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R and Dammacco F . (2002). J. Hematother. Stem Cell Res., 11, 103–118.

  • Zhao Y, Hague S, Manek S, Zhang L, Bicknell R and Rees MC . (1998). Oncogene, 16, 409–415.

Download references

Acknowledgements

This work was supported in part by a grant ‘Interuniversity Funds for Basic Research’ (FIRB) from Ministero dell'Istruzione, dell'Università e della Ricerca, Rome (Italy) to DR and GGN.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Domenico Ribatti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ribatti, D., Guidolin, D., Conconi, M. et al. Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene 22, 6458–6461 (2003). https://doi.org/10.1038/sj.onc.1206789

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206789

Keywords

This article is cited by

Search

Quick links